Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.66 |
| ▸ | CLK1 | P49759 | 1/20 | 0.66 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.66 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | KIT | P10721 | 10/20 | 0.57 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.57 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.55 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12763541 | 0.90 | KIT (0.64) | DYRK1ACLK1DYRK2DYRK1BABL1 | |
| SCHEMBL12763480 | 0.86 | DYRK1A (0.63) | DYRK1ACLK1DYRK2DYRK1BKIT | |
| SCHEMBL8941800 | 0.85 | CLK1 (0.81) | DYRK1ACLK1DYRK2DYRK1BKIT | |
| SCHEMBL8321166 | 0.84 | KIT (0.73) | DYRK1AABL1KITMAP4K1TNIK | |
| SCHEMBL12762997 | 0.84 | DYRK1A (0.62) | DYRK1AABL1KITMAP4K1AAK1 | |
| SCHEMBL12763444 | 0.84 | CLK1 (0.67) | DYRK1ACLK1DYRK2DYRK1BTNIK | |
| SCHEMBL12763228 | 0.84 | ABL1 (0.65) | DYRK1AABL1KITMAP4K1AAK1 | |
| SCHEMBL12763543 | 0.83 | KIT (0.72) | DYRK1AABL1KITMAP4K1AAK1 | |
| SCHEMBL13341945 | 0.82 | KIT (0.73) | DYRK1ACLK1DYRK2DYRK1BABL1 | |
| SCHEMBL12762898 | 0.82 | DYRK1A (0.66) | DYRK1ACLK1DYRK2DYRK1BABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906648-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-2264033-A1 | 3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS | SGX Pharmaceuticals, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090306056-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| US-7601839-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7582637-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090143352-A1 | PYRROLO-PYRIDINE KINASE MODULATIORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090005378-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008124849-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080221119-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-7361764-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361763-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| WO-2007106236-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306056-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K19 | DYRK1A 261/4885CLK1 422/4885DYRK2 227/4885 |
| US-20080221119-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K19 | DYRK1A 261/4885CLK1 422/4885DYRK2 227/4885 |
| US-20090005378-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K19 | DYRK1A 261/4885CLK1 422/4885DYRK2 227/4885 |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | MAP3K20, MAP4K2, MAP3K6 | DYRK1A 673/4885CLK1 515/4885DYRK2 614/4885 |
| US-20090143352-A1 | PYRROLO-PYRIDINE KINASE MODULATIORS | MAP4K2, PDXK, MAP4K1 | DYRK1A 279/4885CLK1 421/4885DYRK2 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.